Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimodivir safety and PK in healthy Japanese adults
NCT02418559Phase 1Completed
- Sponsor
- Johnson & Johnson
- Start
- May 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pimodivir in Influenza A (IAV) (3 arms), sponsored by Johnson & Johnson. Primary endpoints: Maximum Plasma Concentration at 96 hours, Time to Reach the Maximum Plasma Concentration at 96 hours and 2 more. Started May 2015; status: completed.
02
Drugs
pimodivir
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT02418559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02418559.